Testing for Vancomycin Susceptibility

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile (online CE course)
Testing for Vancomycin Susceptibility

The current CLSI recommendation is that MIC tests should be performed to determine the susceptibility of staphylococci to vancomycin. The disk test does not differentiate vancomycin-susceptible isolates of S. aureus from vancomycin-intermediate strains.

Disk diffusion will detect S. aureus isolates containing the VanA vancomycin-resistance gene (VRSA). These isolates will show no zone of inhibition around the disk (zone = 6mm); their identification should be confirmed. Isolates producing vancomycin zones > 7mm should not be reported as susceptible without performing a vancomycin MIC test.

Recommended methods are CLSI Broth Microdilution, Agar Dilution, and Etest® with inoculum prepared to match McFarland 0.5 turbidity standard. The Etest® is considered the most discriminatory of these methods as it allows for visualization of small colonies around zones of inhibition. A pure culture MUST be used. Repeat test for confirmation.

The CLSI recommends that the inoculum should be prepared using the direct suspension method and plates incubated for a full 24 hours in ambient air at 35° C.

Screening for vancomycin resistance in Staphylococci (MIC's > 8 µg/mL) can be performed utilizing a vancomycin agar screening plate – BHI (brain heart infusion) agar containing 6 mg/mL vancomycin. However testing on BHI screening agar does not reliably detect all vancomycin intermediate S. aureus strains.